Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Bladder Cancer Clinical Trial

Official title:

Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03558087
• Other study ID #: HCRN GU16-257
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: July 13, 2018
• Est. completion date: August 2024

Study information

• Verified date: October 2023
• Source: Hoosier Cancer Research Network
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 76
• Est. completion date: August 2024
• Est. primary completion date: March 18, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• ECOG Performance Status of = 1 within 28 days prior to registration.
• Histological evidence of clinically localized muscle-invasive urothelial cancer of the bladder (i.e., ct2-4n0m0). candidate for cystectomy as per treating physician.
• Demonstrate adequate organ function per listed criteria:
• Absolute Neutrophil Count (ANC): = 1.5 x 10^9/L
• Hemoglobin (Hgb): = 9 g/dL
• Platelets: = 100 x 10^9/L
• Calculated creatinine clearance: Creatinine = 1.5 or creatinine clearance = 60 mL/min
• Bilirubin: = 1.5 × upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
• Aspartate aminotransferase (AST) : = 3 × ULN
• Alanine aminotransferase (ALT) : = 3 × ULN
• All subjects must have adequate archival tissue identified at screening (i.e., at least 15 unstained slides or paraffin block). Subjects without available archival tissue must be discussed with the sponsor-investigator.
• Women of childbearing potential must have a negative serum or urine pregnancy within 7 days prior to C1D1. NOTE: "Women of childbearing potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL. NOTE: Women of childbearing potential (WOCBP) receiving nivolumab must be willing to abstain from heterosexual intercourse or to use 2 forms of effective methods of contraception from the time of informed consent to 5 months after the last dose of nivolumab or for the timeframe outlined per package insert for chemotherapy. This timeframe also applies to breastfeeding. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method. Male subjects capable of fathering a child that are sexually active with partners of childbearing potential must be willing to abstain from heterosexual intercourse or to use 2 forms of effective methods of contraception from the time of informed consent to the timeframe outlined per package insert for chemotherapy. Contraception is not required for nivolumab. The timeframes described in the previous 2 sentences apply to sperm donation. Two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method.

Exclusion Criteria:

• Prior treatment with systemic chemotherapy for muscle-invasive urothelial cancer of the bladder
• Active infection requiring systemic therapy
• Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
• Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
• Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
• Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
• Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
• Grade = 2 neuropathy (NCI CTCAE version 4).
• Prior radiation therapy for bladder cancer
• Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (RNA) or hepatitis C antibody (HCV antibody) indicating acute or chronic infection.
• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
• Evidence of interstitial lung disease or active, non-infectious pneumonitis.
• Solid organ or allogeneic stem cell transplant

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• Nivolumab
Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
• Gemcitabine
Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.
• Cisplatin
Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.

Locations

Country	Name	City	State
United States	City of Hope	Duarte	California
United States	Univerity of Southern California	Los Angeles	California
United States	University of Wisconsin	Madison	Wisconsin
United States	Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center	New York	New York
United States	Penn Medicine Abramson Cancer Center	Philadelphia	Pennsylvania
United States	Oregon Health & Science University	Portland	Oregon
United States	Huntsman Cancer Institute University of Utah	Salt Lake City	Utah

Sponsors (3)

Lead Sponsor	Collaborator
Matthew Galsky	Bristol-Myers Squibb, Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the clinical complete response rate (cT0 or cTa) with gemcitabine, cisplatin, plus nivolumab	Clinical complete response rate will be defined as cT0 or cTa disease after gemcitabine, cisplatin, plus nivolumab.	24 months
Primary	Determine the ability of clinical complete response (cT0 or cTa) to predict benefit from treatment.	Benefit will be defined as a pathologic complete response (	24 months
Secondary	Assess Adverse Events	Assess adverse events according to the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) v4	24 months
Secondary	Bladder intact overall survival	Bladder-intact overall survival is defined as the time from initiation of treatment until death or cystectomy	24 Months
Secondary	Recurrence-free survival	Recurrence-free survival is defined as the time from initiation of treatment to death or recurrence, depending on which occurs first	24 months
Secondary	Pathologic complete response rate in patients undergoing cystectomy	Pathologic complete response rate in patients undergoing radical cystectomy is defined as the proportion of patients with	24 Months
Secondary	Determine the association between a prespecified panel of genomic biomarkers and benefit from treatment in patients achieving a clinical complete response.	Benefit will be defined as a pathologic complete response (p	24 months